相似文献
1
The potential of combined mutation sequencing of plasma circulating cell-free DNA and matched white blood cells for treatment response prediction.
Mol Oncol. 2020 Mar;14(3):487-489. doi: 10.1002/1878-0261.12646. Epub 2020 Feb 23.
2
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
Clin Cancer Res. 2023 Mar 1;29(5):899-909. doi: 10.1158/1078-0432.CCR-22-2538.
3
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Nat Med. 2019 Dec;25(12):1928-1937. doi: 10.1038/s41591-019-0652-7. Epub 2019 Nov 25.
4
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma.
Genet Med. 2020 Aug;22(8):1366-1373. doi: 10.1038/s41436-020-0801-x. Epub 2020 Apr 28.
5
Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
Cancer Med. 2023 Sep;12(17):17632-17637. doi: 10.1002/cam4.6380. Epub 2023 Aug 17.
6
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
JCO Precis Oncol. 2022 Jul;6:e2200012. doi: 10.1200/PO.22.00012.
7
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Mol Diagn Ther. 2023 Nov;27(6):753-768. doi: 10.1007/s40291-023-00670-1. Epub 2023 Aug 26.
8
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629.
9
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Clin Cancer Res. 2018 Aug 1;24(15):3528-3538. doi: 10.1158/1078-0432.CCR-17-3837. Epub 2018 May 18.
10
Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Cancer Genet. 2021 Nov;258-259:93-100. doi: 10.1016/j.cancergen.2021.08.005. Epub 2021 Aug 30.
引用本文的文献
1
Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer.
ESMO Open. 2023 Dec;8(6):102051. doi: 10.1016/j.esmoop.2023.102051. Epub 2023 Nov 10.
2
Liquid Profiling for Cancer Patient Stratification in Precision Medicine-Current Status and Challenges for Successful Implementation in Standard Care.
Diagnostics (Basel). 2022 Mar 19;12(3):748. doi: 10.3390/diagnostics12030748.
3
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25.
4
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Oncologist. 2021 Nov;26(11):e1971-e1981. doi: 10.1002/onco.13905. Epub 2021 Aug 4.
5
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.
Cancers (Basel). 2020 Oct 16;12(10):3002. doi: 10.3390/cancers12103002.
6
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening.
Adv Sci (Weinh). 2020 Jul 29;7(18):2000486. doi: 10.1002/advs.202000486. eCollection 2020 Sep.
7
Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy.
Mol Oncol. 2020 Aug;14(8):1719-1730. doi: 10.1002/1878-0261.12727. Epub 2020 Jun 8.
8
Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.
Cancers (Basel). 2020 May 13;12(5):1222. doi: 10.3390/cancers12051222.
本文引用的文献
1
Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance.
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00191.
2
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Mol Oncol. 2020 Mar;14(3):490-503. doi: 10.1002/1878-0261.12617. Epub 2020 Feb 7.
3
Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway.
Nat Commun. 2019 Dec 11;10(1):5649. doi: 10.1038/s41467-019-13542-2.
4
Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
Lancet Haematol. 2020 Jan;7(1):e73-e81. doi: 10.1016/S2352-3026(19)30211-X. Epub 2019 Dec 3.
5
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Nat Med. 2019 Dec;25(12):1928-1937. doi: 10.1038/s41591-019-0652-7. Epub 2019 Nov 25.
6
Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
Clin Chem. 2020 Jan 1;66(1):149-160. doi: 10.1373/clinchem.2019.306837.
7
Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.
Cancers (Basel). 2019 Aug 14;11(8):1171. doi: 10.3390/cancers11081171.
8
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Cell Mol Life Sci. 2020 Feb;77(3):497-509. doi: 10.1007/s00018-019-03189-z. Epub 2019 Jun 28.
9
Liquid biopsy and minimal residual disease - latest advances and implications for cure.
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3.
10
Current and future perspectives of liquid biopsies in genomics-driven oncology.
Nat Rev Genet. 2019 Feb;20(2):71-88. doi: 10.1038/s41576-018-0071-5.
Zotero 插件